It’s March 19, and Erica Barnell, MD/PhD ’23, knows her company’s position could change dramatically soon. Barnell, co-founder and chief medical and science officer of Geneoscopy, is awaiting a decision letter from the Food and Drug Administration (FDA) for approval of ColoSense, the company’s noninvasive, multitarget RNA-based screening test for colorectal cancer…
